Authors
Latest:
Structural Capabilities in Small and Medium-Sized Patient-Centered Medical HomesThirty medical home pilot primary care practices had high structural capabilities at baseline and performance improved substantially after 24 months in practices starting with lower capabilities.
Latest:
Long-Term Statin Use and the Risk of Parkinson's DiseaseThis historical cohort study demonstrates that long-term statin use is associated with a significant decrease in the incidence of Parkinson's disease.
Latest:
Compliance, Persistence, and Switching Patterns for ACE Inhibitors and ARBsThis drug-utilization study in a prescription database of more than 50,000 patients analyzed compliance, persistence, and switching behavior for ACE inhibitors and ARBs.
Latest:
Variation in US Outpatient Antibiotic Prescribing Quality Measures According to Health Plan and GeographyAntibiotic prescribing has become viewed as a patient safety and quality-of-care issue. The authors analyzed quality measures related to appropriate antibiotic prescribing and testing.
Latest:
Validation of a Claims-Based Algorithm to Characterize Episodes of CareThe Michigan Value Collaborative has created a claims-based algorithm that categorizes claims into episode components. This manuscript describes the validation of this algorithm.
Latest:
Major Depression Associated With Rates of Cardiovascular Disease State TransitionsPatients with major depression had faster transitions to both early and later stages of cardiovascular disease than patients without major depression.
Latest:
Medical Loss Ratio’s Role in the Large Group Insurer MarketThe authors used medical loss ratio forms to assess trends in premiums, medical claims, administrative costs, quality improvement, and margins in the large group insurer market.
Latest:
Identifying Children at Risk of Asthma Exacerbations: Beyond HEDISAnalysis of insurance claims reveals that criteria other than the Healthcare Effectiveness Data and Information Set (HEDIS) persistent asthma definition can identify more at-risk patients with reasonable loss of specificity.
Latest:
The Long-term Social Value of Granulocyte Colony-Stimulating FactorsAlthough currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Latest:
Electronic Health Record Problem Lists: Accurate Enough for Risk Adjustment?Electronic health record (EHR)-based comorbidity assessment had low sensitivity for identifying major comorbidities and poorly predicted survival. EHR-based comorbidity data require validation prior to application to risk adjustment.
Latest:
"No-Shows": Who Fails to Follow Up With Initial Behavioral Health Treatment?Patients who obtained authorization but did not get initial mental health treatment needed treatment as much as or more than patients who presented for care.
Latest:
Current Value-Based Care Models Need Greater Emphasis on Specialty CareThis article provides an overview of the impact of specialty care and the opportunity for it to leapfrog primary care as a lead focus for accountable care.
Latest:
A Web-Based Clinical Decision Support System for Depression Care ManagementThis article describes the development and capabilities of a Webbased decision support system for care managers working in the context of the chronic care model.
Latest:
Sustainable Lifelines: Supporting Integrated Behavioral Health Services for Children and Adolescents in the Accountable Care EraA reimbursement strategy for collaborative care models is presented to enhance access to integrated behavioral healthcare for children and adolescents from underserved areas.
Latest:
Bending the Curve Through Health Reform ImplementationAuthors from The Brookings Institution update their recommendations by focusing on 3 concrete objectives to slow spending and improve quality of care within the next 5 years.
Latest:
Addressing Oncologists' Gaps in the Use of Biosimilar ProductsThe availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological products had been approved by the FDA, including 4 biosimilars for trastuzumab, 3 each for infliximab and adalimumab, 2 each for pegfilgrastim and filgrastim, and 1 each for rituximab, epoetin alfa, bevacizumab, and etanercept. The pace of approvals has accelerated, from the first indication for a filgrastim biosimilar in 2015 to 3 approvals in 2016, 5 in 2017, and 9 through early 2019, 7 of which were announced in the 2018 calendar year.
